New research from the Washington University School of Medicine reveals insight into possibly counteracting inappropriate mucus production in conditions such as asthma and chronic obstructive pulmonary disease (COPD).
Publicly insured Americans who undergo lung transplantation for cystic fibrosis fare markedly worse in the long run than privately insured Americans.
Sollpura (liprotamase) is an investigational enzyme therapy appropriated for those with lower levels of digestive enzyme, or Exocrine Pancreatic Insufficiency (EPI) caused by several diseases, including cystic fibrosis.
The US FDA has expanded the approved use of Kalydeco for children aged two to five years with cystic fibrosis who have one of 10 mutations in their CFTR gene.
Using stem cells derived from skins of cystic fibrosis patients, scientists have generated organoid models of the distal part of lung tissue that may help them understand more about the disease.
In a first-of-its-kind study published in the ERJ, researchers have provided forecasts for the number of adults living with cystic fibrosis in 34 different European countries by the year 2025.
A team of researchers have found why mucus in the lungs of cystic fibrosis patients thickens, which makes them more vulnerable to lung infection.
UNC researchers have identified genetic pathways that play major roles in the severity of cystic fibrosis.
A chemical known as allicin that is found in garlic can kill bacteria that cause life-threatening lung infections in people with cystic fibrosis, research suggests.
Researchers are recruiting participants for a clinical trial designed to assess the sensation of shortness of breath (dyspnea) in patients with cystic fibrosis during exercise.
Arkansas Medicaid has settled a federal lawsuit brought by patients denied the cystic fibrosis (CF) drug Kalydeco due its high cost.
Celtaxsys, Inc, a clinical stage biotechnology company, announced that the FDA has granted orphan drug designation to its cystic fibrosis treatment drug leukotriene A4 hydrolase inhibitor.
During the recent state of the union address, President Obama highlighted cystic fibrosis as a model for the government's strategy for precision medicine and treatment.
Shire has just announced a new partnership with the Cystic Fibrosis Foundation to develop technology that can maintain lung function and protect against respiratory infections.
PulmoFlow Inc's Kitabis Pak, a co-packaging of generic tobramycin inhalation solution with a PARI LC PLUS Nebulizer, has been approved to treat cystic fibrosis.
Gone are the days when an RT had to use muscle alone to clear lung secretions. Technology has made this more efficient, effective, and patient friendly.
Researchers have shown for the first time how bacteria can grow directly in the lungs of cystic fibrosis patients, which has provided tremendous insights into bacteria behavior and growth in chronic infections.
Researchers have discovered an inhibitor for an enzyme called Sphingomyelin phosphodiesterase C (SMaseC) which is produced by the S. aureus bacterium and may harm the health of CF patients.
A team of international researchers found that the immunological cell surface molecule HLA-DQ is reduced or absent in many cystic fibrosis patients.
Scientists now have shown that many of the adult patients with cystic fibrosis in addition lack a cell surface molecule, important for immune defence.